NCT04960332

Brief Summary

The purpose of this research project is to improve the surgical treatment of Soft Tissue Sarcoma (STS) treatment based upon a Randomized Controlled Trial (RCT). We want to evaluate the effect of the use of Negative Pressure Wound Therapy (NPWT) versus a conventional wound dressing on postoperative wound complications after surgical removal of deep-seated high-malignant STS of the extremities or trunk wall.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
160

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 26, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

July 1, 2021

Completed
12 days until next milestone

First Posted

Study publicly available on registry

July 13, 2021

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

July 6, 2022

Status Verified

July 1, 2022

Enrollment Period

2.4 years

First QC Date

May 26, 2021

Last Update Submit

July 1, 2022

Conditions

Keywords

Negative Pressure Wound TherapyPrevenaSarcomaCancerNeoplasms, Connective and Soft Tissue

Outcome Measures

Primary Outcomes (1)

  • Wound complication/healing

    A major wound complication defined as in O'Sullivan et al. \[11\]: * A secondary surgery under anesthesia for wound repairs such as debridement, operative drainage and secondary wound closure. * Wound management without secondary surgery, this includes invasive procedure without anesthesia such as aspiration of seroma and readmission for wound care such as intravenous antibiotic or persistent deep packing within 4 months (120 days) after surgery.

    120 days postoperatively

Secondary Outcomes (8)

  • Secondary outcome measures, hospital stay.

    1 year postoperatively

  • Secondary outcome measures, readmission.

    1 year postoperatively

  • Secondary outcome measures, primary wound healing.

    1 year postoperatively

  • Secondary outcome measures, deep infection.

    1 year postoperatively

  • Secondary outcome measures, seroma.

    1 year postoperatively

  • +3 more secondary outcomes

Study Arms (2)

Standard treatment

NO INTERVENTION

Group A: Standard wound closure with staples and conventional wound dressing.

Prevena

EXPERIMENTAL

Group B: Wound closure with staples and Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System).

Device: Prevena

Interventions

PrevenaDEVICE

RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.

Prevena

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- Surgery for a deep-seated STS of an extremity or the trunk wall at Rigshospitalet.

You may not qualify if:

  • Age \< 18 years
  • Wound closure not possible without plastic surgery (pedicled or free flaps)
  • Low malignant (Trojani grade 1) STS or borderline tumors
  • Pre- or postoperative chemotherapy
  • Preoperative radiotherapy to the local site.
  • Allergic or hypersensitive to acrylic adhesives or silver
  • Unwilling or unable to provide informed consent
  • Inability to comply with planned study procedures
  • Patients with metastatic disease.
  • Patients with ischemic surgery such as bypass or endovascular prosthesis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Aarhus University Hospital

Aarhus, 8200, Denmark

RECRUITING

Rigshospitalet

Copenhagen, Denmark

RECRUITING

Related Publications (1)

  • Yilmaz M, Thorn A, Sorensen MS, Jensen CL, Petersen MM. Effect of negative pressure wound therapy after surgical removal of deep-seated high-malignant soft tissue sarcomas of the extremities and trunk wall-study protocol for a randomized controlled trial. Trials. 2022 Jun 18;23(1):507. doi: 10.1186/s13063-022-06468-6.

MeSH Terms

Conditions

SarcomaNeoplasmsNeoplasms, Connective and Soft Tissue

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type

Study Officials

  • Andrea Thorn, MD

    Rigshospitalet, Denmark

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Prospective randomized controlled trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD student and Medical Doctor, department of orthopedic surgery

Study Record Dates

First Submitted

May 26, 2021

First Posted

July 13, 2021

Study Start

July 1, 2021

Primary Completion

December 1, 2023

Study Completion

December 1, 2024

Last Updated

July 6, 2022

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will not share

The regulation from data protection regulation and data protection act will always be followed and a permission from data protection agency have been obtained (P-2021-150).

Locations